Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

INSIDE INFORMATION – BUSINESS UPDATES

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the "**Company**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") as well as the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to announce that, on December 3, 2021, two of the Company's innovative medicines have been included in the updated National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration of the People's Republic of China (NHSA), including its dual-targeted TACI-Fc fusion protein telitacicept (RC18, Brand Name: 泰爱®) and anti-HER2 antibody-drug conjugate (ADC) disitamab vedotin (RC48, Brand Name: 爱地希®).

ABOUT TELITACICEPT (RC18, BRAND NAME: 泰爱®)

Telitacicept (RC18, Brand Name: 泰爱®) is a proprietary novel fusion protein of us to treat autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept targets two cell-signaling molecules critical for B-lymphocyte development: B-cell lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune diseases.

It was granted conditional marketing approval by the National Medical Products Administration of the People's Republic of China (NMPA) to treat systemic lupus erythematosus (SLE) on March 11, 2021. The Company is currently conducting a number of phase II or III clinical studies for telitacicept to treat other indications within the autoimmune disease area, in an attempt to address the significant unmet or underserved medical needs in this therapeutic area.

ABOUT DISITAMAB VEDOTIN (RC48, BRAND NAME: 爱地希®)

Disitamab vedotin (RC48, Brand Name: 爱地希®) is an anti-HER2 ADC targeting prevalent cancers with significant unmet medical needs, and it is the first domestically developed ADC in China to receive marketing approval. It was granted conditional marketing approval by the NMPA to treat locally advanced or metastatic gastric cancer (GEJ carcinoma) in China on June 9, 2021. In addition, its New Drug Application (NDA) for the treatment of HER2 expressing locally advanced or metastatic urothelial carcinoma was accepted by NMPA on July 14, 2021.

Disitamab vedotin has received the breakthrough therapy and fast track designations for treatment of locally advanced or metastatic urothelial carcinoma by the Food and Drug Administration (FDA). It has also received breakthrough therapy designations for both HER2 expressing locally advanced or metastatic urothelial carcinoma and HER2 positive breast cancer with liver metastasis patients previously treated with trastuzumab and taxane by the NMPA.

The Company is implementing a differentiated development and commercial strategy for disitamab vedotin, targeting prevalent HER2 expressing indications that are currently underserved, including (i) gastric cancer (GC); (ii) urothelial carcinoma (UC); (iii) breast cancer (BC); and (iv) other cancer indications expressed by HER2.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the telitacicept (RC18, Brand Name: 泰爱®) and disitamab vedotin (RC48, Brand Name: 爱地希®) (for the treatment of other indications) will ultimately be successfully marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
RemeGen Co., Ltd.
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
December 3, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

* *For identification purposes only*